ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LUNG vs PYPD // REVENUE GROWTH (YOY)

Pulmonx Corporation (NASDAQ) VS. PolyPid Ltd. (NASDAQ) • 15-METRIC TALLY: LUNG 4 — PYPD 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LUNG VS. PYPD) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LUNG PYPD SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 74.20% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -24.15% -24.74% +0.59 LUNG /fcf-yield <GO>
Operating Margin -59.30% — — TIE /operating-margins <GO>
Net Profit Margin -59.70% — — TIE /net-margins <GO>
Revenue Growth (YoY) ACTIVE 8.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 2/9 +4.00 LUNG /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 79.1 59.3 +19.80 LUNG /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $135.9M $113.5M $22.4M LUNG /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LUNG REV PYPD REV LUNG GROSS % PYPD GROSS % LUNG FCF PYPD FCF
FY 2025 $90.5M $0 74.2% — -$32.8M -$28.1M
FY 2024 $83.8M $0 74.0% — -$33.0M -$22.0M
FY 2023 $68.7M $0 — — -$37.6M -$17.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LUNG // BETA —
PYPD // BETA —